Canada - English - Health Canada

pharmascience inc - bosentan (bosentan monohydrate) - tablet - 62.5mg - bosentan (bosentan monohydrate) 62.5mg - vasodilating agents

Canada - English - Health Canada

pharmascience inc - bosentan (bosentan monohydrate) - tablet - 125mg - bosentan (bosentan monohydrate) 125mg - vasodilating agents

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - bosentan monohydrate, quantity: 129.08 mg (equivalent: bosentan, qty 125 mg) - tablet, film coated - excipient ingredients: maize starch; sodium starch glycollate type b; povidone; pregelatinised maize starch; glycerol dibehenate; magnesium stearate; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red; purified water; ethylcellulose; cetyl alcohol; hydrogen peroxide; sodium lauryl sulfate; octamethylcyclotetrasiloxane; silica dimethicone silylate; dimeticone 5000; cyclomethicone - bosentan is indicated for the treatment of: - idiopathic pulmonary arterial hypertension - familial pulmonary arterial hypertension - pulmonary arterial hypertension associated with scleroderma or - pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger's physiology in patients with who functional class ii, iii or iv symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - bosentan monohydrate, quantity: 129.08 mg (equivalent: bosentan, qty 125 mg) - tablet, film coated - excipient ingredients: maize starch; sodium starch glycollate type b; povidone; pregelatinised maize starch; glycerol dibehenate; magnesium stearate; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red; purified water; ethylcellulose; cetyl alcohol; hydrogen peroxide; sodium lauryl sulfate; octamethylcyclotetrasiloxane; silica dimethicone silylate; dimeticone 5000; cyclomethicone - bosentan is indicated for the treatment of: - idiopathic pulmonary arterial hypertension - familial pulmonary arterial hypertension - pulmonary arterial hypertension associated with scleroderma or - pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger's physiology in patients with who functional class ii, iii or iv symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - bosentan monohydrate, quantity: 64.5 mg (equivalent: bosentan, qty 62.5 mg) - tablet, film coated - excipient ingredients: maize starch; sodium starch glycollate type b; povidone; pregelatinised maize starch; glycerol dibehenate; magnesium stearate; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red; purified water; ethylcellulose; cetyl alcohol; hydrogen peroxide; sodium lauryl sulfate; octamethylcyclotetrasiloxane; silica dimethicone silylate; dimeticone 5000; cyclomethicone - bosentan is indicated for the treatment of: - idiopathic pulmonary arterial hypertension - familial pulmonary arterial hypertension - pulmonary arterial hypertension associated with scleroderma or - pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger's physiology in patients with who functional class ii, iii or iv symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - bosentan monohydrate, quantity: 64.5 mg (equivalent: bosentan, qty 62.5 mg) - tablet, film coated - excipient ingredients: maize starch; sodium starch glycollate type b; povidone; pregelatinised maize starch; glycerol dibehenate; magnesium stearate; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red; purified water; ethylcellulose; cetyl alcohol; hydrogen peroxide; sodium lauryl sulfate; octamethylcyclotetrasiloxane; silica dimethicone silylate; dimeticone 5000; cyclomethicone - bosentan is indicated for the treatment of: - idiopathic pulmonary arterial hypertension - familial pulmonary arterial hypertension - pulmonary arterial hypertension associated with scleroderma or - pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger's physiology in patients with who functional class ii, iii or iv symptoms.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - bosentan monohydrate 129.082mg equivalent to bosentan anhydrous 125 mg;  ; bosentan monohydrate 129.082mg equivalent to bosentan anhydrous 125 mg - film coated tablet - 125 mg - active: bosentan monohydrate 129.082mg equivalent to bosentan anhydrous 125 mg   excipient: glyceryl behenate magnesium stearate maize starch opadry yellow 03k82318 povidone sodium laurilsulfate sodium starch glycolate starch surelease clear e-7-19040 as solid active: bosentan monohydrate 129.082mg equivalent to bosentan anhydrous 125 mg excipient: glyceryl behenate magnesium stearate maize starch opadry white 03k580000 povidone sodium laurilsulfate sodium starch glycolate starch surelease clear e-7-19040 as solid - indicated for the treatment of idiopathic pulmonary arterial hypertension, familial pulmonary arterial hypertension, pulmonary arterial hypertension associated with scleroderma or pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger's physiology in patients with who class iii or iv symptoms.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - bosentan monohydrate 64.541mg equivalent to bosentan anhydrous 62.5 mg;  ; bosentan monohydrate 64.541mg equivalent to bosentan anhydrous 62.5 mg - film coated tablet - 62.5 mg - active: bosentan monohydrate 64.541mg equivalent to bosentan anhydrous 62.5 mg   excipient: glyceryl behenate magnesium stearate maize starch opadry yellow 03k82318 povidone sodium laurilsulfate sodium starch glycolate starch surelease clear e-7-19040 as solid active: bosentan monohydrate 64.541mg equivalent to bosentan anhydrous 62.5 mg excipient: glyceryl behenate magnesium stearate maize starch opadry white 03k580000 povidone sodium laurilsulfate sodium starch glycolate starch surelease clear e-7-19040 as solid - indicated for the treatment of idiopathic pulmonary arterial hypertension, familial pulmonary arterial hypertension, pulmonary arterial hypertension associated with scleroderma or pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger's physiology in patients with who class iii or iv symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - bosentan monohydrate, quantity: 64.541 mg - tablet, film coated - excipient ingredients: sodium lauryl sulfate; glyceryl behenate; povidone; maize starch; pregelatinised maize starch; magnesium stearate; sodium starch glycollate type a; titanium dioxide; hypromellose; purified talc; triacetin; purified water; strong ammonia solution; ethylcellulose; oleic acid; medium chain triglycerides - bosentan viatris is indicated for the treatment of,? idiopathic pulmonary arterial hypertension,? familial pulmonary arterial hypertension,? pulmonary arterial hypertension associated with scleroderma or,? pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger?s physiology ,in patients with who functional class ii, iii or iv symptoms

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - bosentan monohydrate, quantity: 129.082 mg - tablet, film coated - excipient ingredients: povidone; magnesium stearate; maize starch; pregelatinised maize starch; sodium starch glycollate type a; sodium lauryl sulfate; glyceryl behenate; titanium dioxide; hypromellose; purified talc; triacetin; purified water; strong ammonia solution; ethylcellulose; oleic acid; medium chain triglycerides - bosentan viatris is indicated for the treatment of,? idiopathic pulmonary arterial hypertension,? familial pulmonary arterial hypertension,? pulmonary arterial hypertension associated with scleroderma or,? pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger?s physiology ,in patients with who functional class ii, iii or iv symptoms